Behavioural changes and psychological symptoms in dementia disorders (Q36292518)

13 August 2017

1 reference

title

Behavioural changes and psychological symptoms in dementia disorders (English)

1 reference

13 August 2017

0 references

1 reference

2

Jeffrey Cummings

1 reference

13 August 2017

0 references

Ian McKeith

1

1 reference

13 August 2017

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

11

1 reference

13 August 2017

735-742

1 reference

Dementia as a predictor of functional disability: a four-year follow-up study.

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Use of the QOL-AD for measuring quality of life in people with severe dementia--the LASER-AD study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Fronto-temporal dementia: nosology, neuropsychology, and neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The spectrum of behavioral changes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Apathy is not depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Cornell Scale for Depression in Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Agitated behaviors in the elderly. I. A conceptual review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Frontotemporal behavioral scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Features of regional cerebral glucose metabolism abnormality in corticobasal degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Frontotemporal dementia and Alzheimer's disease: retrospective differentiation using information from informants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Operational criteria for senile dementia of Lewy body type (SDLT)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Dementia with lewy bodies: findings from an international multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Vascular cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Poststroke depression and lesion location revisited.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Alzheimer disease and frontotemporal dementias. Behavioral distinctions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Distinct behavioural profiles in frontotemporal dementia and semantic dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Repetitive and compulsive behavior in frontal lobe degenerations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Neuroanatomy of the self: evidence from patients with frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The influence of right frontotemporal dysfunction on social behavior in frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Behavioral disorders in the frontal and temporal variants of frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Statistical analysis of hippocampal asymmetry in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Impact of training dementia caregivers in sensitivity to nonverbal emotion signals.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Nonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Meta-analysis of psychosocial interventions for caregivers of people with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The needs of the caregiver in the long-term treatment of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

Toward a molecular neuropsychiatry of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970219-2

7 January 2021

10.1016/S1474-4422(05)70219-2

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16239180